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For a better understanding of the acute pathogenicity of SHIV-89.6P stock virus, which induces prominent CD4 cell loss
within a month after inoculation in monkeys, we have constructed four infectious molecular clones (cl 18, cl 64, cl 69, and
cl 71). Cl 64, cl 69, and cl 71, like the parental virus, showed a high in vitro replication ability and a pathogenic-like effect (CD4
downmodulation) in a monkey CD41 cell line, whereas cl 18 showed a lower replication ability and could not downmodulate
CD4. Cl 64, which has characteristics similar to those of the parental virus in vitro, was inoculated into four rhesus monkeys.
All monkeys showed a plasma viral load similar to that of the parental virus with a peak at 2 weeks after inoculation. However,
the viral load gradually decreased and the virus failed to cause an AIDS-like disease in infected monkeys, but it induced a
strong antiviral antibody response. These results demonstrate the polyclonal nature of the parental SHIV-89.6P virus stock
and demonstrate that cl 64, aside from its high replicability, may differ qualitatively from the parental virus. © 2001 Academic
PressINTRODUCTION
Infection of Asian macaques with simian immuno-
deficiency virus (SIVmac) has provided a useful model
for understanding the pathogenesis of AIDS in human
immunodeficiency virus type 1 (HIV-1)-infected hu-
mans. However, differences between the SIVmac and
the HIV-1 viral genomes have limited the utility of this
model for HIV-1 pathogenesis investigation (Kanki et
al., 1985; Murphy-Corb et al., 1986). Nevertheless, the
problem was partially overcome by recent construc-
tion of SIV/HIV chimeric viruses (SHIVs), which have
most of the 39 half of the HIV-1 genome including vpr,
tat, rev, vpu, and env genes. These chimeric viruses
have provided a critical tool for understanding HIV-1
pathogenesis in vivo. Although many of the SHIVs
were infectious for macaque monkeys, only a few were
found to be pathogenic (Reimann et al., 1996a; Cay-
abyab et al., 1999; McCormick-Davis et al., 1998; Luciw
et al., 1999).
One of the pathogenic SHIVs, SHIV-89.6P, was pre-
pared by several passages in vivo (Reimann et al.,
1996a). The virus induced rapid CD4 lymphopenia and
an AIDS-like illness in most of the recipient monkeys
at an early stage of infection. An infectious molecular
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6clone, KB9, which induced rapid depletion of CD41
lymphocytes in rhesus monkeys, was obtained from
the SHIV-89.6P parental virus (Karlsson et al., 1997).
However, subsequent investigations revealed that only
30% of the monkeys inoculated with KB9 developed
AIDS, whereas 100% of the monkeys inoculated with
parental SHIV-89.6P virus acquired the disease
(Reimann et al., 1999). The other KB9-inoculated mon-
keys showed a partial drop in CD41 T lymphocyte cell
numbers with subsequent recovery to the preinfection
state. A similar early infection state has been ob-
served at the early stages of (1) natural HIV-1 infection
in humans, (2) pathogenic SIV infection in monkeys,
and (3) infection with molecularly cloned pathogenic
SIVmac239 in macaques (Evans et al., 1999). Still,
there is a rather large difference in the pathogenicities
of the molecularly cloned virus and the uncloned pa-
rental SHIV-89.6P. Further detailed analysis is needed
to clarify the acute pathogenic features of SHIV-89.6P
stock virus.
The goal of the present study was to better under-
stand the acute pathogenic features of the SHIV-89.6P
stock virus to determine whether this virus can be a
useful monkey model for AIDS pathogenesis. To do
this, we constructed four molecular clones having the
SHIV-89.6P-derived 39 half of the genome. We then
compared their pathogenicities with those of the pa-
rental virus and two other viruses (the chronic patho-
genic SIVmac and the nonpathogenic SHIV-NM-3rN),
in vitro and in vivo.
Cw
m
m
t
F
m
p
(
a
1
A
s
m
i
7LESS PATHOGENIC CLONES FROM SHIV-89.6PRESULTS
onstruction and in vitro characterization of SHIV-
89.6P molecular clones
In order to construct molecular clones of the SHIV-
89.6P pathogenic virus, the proviral DNA was isolated
from M8166 cells that had been infected with parental
SHIV-89.6P viral stock and were used as a template for
the polymerase chain reaction to amplify the 4 kb of the
39 half of SHIV-89.6P, which includes vpr, vpu, tat, rev,
env, nef, and 39-LTR. The obtained 39 half of SHIV-89.6P
was ligated to the 59 half (59-LTR, gag, pol, vif, and vpx) of
a SIVmac239 molecular clone. Finally, four molecular
clones (cl 18, cl 64, cl 69, and cl 71) were constructed,
whose restriction patterns were confirmed by digestion
with different restriction enzymes specific for the se-
quenced SHIV-89.6P KB9 molecular clone (Karlsson et
al., 1997).
The plasmid DNAs of the four obtained molecular
clones were transfected into M8166 cells in order to
produce infectious viral stocks. Subsequently, the simian
CD41 T cell line HSC-F and cultured monkey PBMCs
ere infected with 103 TCID50 of the obtained infectious
viral stock of each virus (Fig. 1). All infected cultures
exhibiting increasing reverse transcriptase (RT) produc-
tion in the time course were identified. At the times of
their peak replication, cl 64 and cl 71 were observed at
higher titers than were cl 18 and cl 69. The titers of the
replication peaks of cl 64 and cl 71 were similar to the
titer of the replication peak of parental SHIV-89.6P virus
in HSC-F cells. The peak replication of cl 64 in monkey
PBMCs was lower, but occurred earlier than that of the
parental SHIV-89.6P. All of the 89.6P-derived virus clones
except cl 69 replicated in vitro in monkey PBMCs to a
much higher titer than did the SIVmac239 or NM-3rN
viruses.
Cytopathogenicity and CD4 downmodulation in the
HSC-F cell line
In the present study, the HSC-F cell line was found to
lose CD4 molecules when it was infected with strongly
pathogenic SHIV-89.6P, which also caused severe CPE
and killed many cells (Fig. 2). The chronic pathogenic
virus SIVmac239 killed a significant amount of cells but
caused no CD4 downmodulation. In addition, the non-
pathogenic SHIV-NM3rN killed very few cells and
showed no CD4 downmodulation, as shown by the flow
cytometry analysis. All four newly obtained SHIV-89.6P
clones were tested for the ability to kill cells and to
downmodulate CD4 in HSC-F cells. Three of the four
clones (cl 64, cl 69, and cl 71) were as effective as the
parental SHIV-89.6P in killing the cells and reducing the
CD4 molecules in HSC-F cells in vitro, while the other
clone (cl 18) did not kill the cells or reduce CD4.Infection of rhesus monkeys with a cloned SHIV-
89.6P
The ability of the molecularly cloned SHIV-89.6P to
infect and to cause CD41 lymphocyte depletion in rhesus
onkeys was examined (Fig. 3). Cl 64 was chosen for
onkey infection because of its demonstrated advan-
age in replication and CD4 downmodulation in vitro.
our animals were inoculated intravenously. To deter-
ine whether the pathogenesis of the cloned virus de-
ends on the inoculated dose, one pair of monkeys
MM210 and MM215) was inoculated with 90 TCID50 and
nother pair (MM189 and MM200) was inoculated with
05 TCID50. However, cl 64 showed no dose dependency.
lso, the infection course was similar to that at the early
tage in humans naturally infected with HIV-1 and in
onkeys with chronic pathogenic SIVs in that there was
ncomplete degradation of CD41 cells with a subsequent
tendency to recover the normal CD41 cell number. All
four monkeys showed partial or complete recovery to the
FIG. 1. Comparison of the in vitro replication kinetics of SIVmac239,
SHIV-NM-3rN, and SHIV-89.6P and its molecular clones (cl 18, 64, 69,
and 71). Replication kinetics was determined by reverse transcriptase
activity assay of the culture supernatant. Data are expressed as the
mean values of results from repeated assays with standard deviation.
(A) Replication in HSC-F cells. (B) Replication in macaque PBMCs.preinfection state. In all cases, the peak of cl 64 replica-
tion, monitored by plasma viral RNA levels, was ob-
for each virus is a dot plot showing the CD4/CD8 status of the cells. Upper and
and right and left areas show CD8-positive and CD8-negative cells, respectiv
absolute numbers of CD4 lymphocytes per microliter in each monkey
with standard deviation.
8 KOZYREV ET AL.served at the same time (2 weeks postinoculation), and
the replication was to a titer similar to that of the parental
SHIV-89.6P (Fig. 4). Despite the high peaks of replication,
the plasma viral RNA level of cl 64 decreased substan-
tially by 6 to 10 weeks postinfection in each of the
infected monkeys. In contrast, the parental virus contin-
ued to replicate in MM130 and MM131 at high levels
even after 13 weeks. All four infected monkeys tested
positive for the virus soon after inoculation, and contin-
ued to test positive until 13 weeks postinfection. Subse-
quently, the virus could not be recovered from CD8-
depleted lymphocytes in vitro. Anti-HIV-1 antibody pro-
duction was measured by particle agglutination assay
(Table 1). The monkeys were found to develop strong
antibody responses to cl 64, with very high anti-HIV-1
antibody titers 3 weeks postinfection, although no anti-
body response was detected in parental virus-infected
monkeys. Clinically, all animals inoculated with the
lation of CD4 surface marker on HSC-F cells infected with different
ak virus replication. Upper histogram for each virus shows the number
amounts of dead and live HSC-F cells, respectively. The lower graph
lower areas show CD4-positive and CD4-negative cells, respectively,
ely. Cl 64, 69, and 71 showed almost the same results.FIG. 2. Flow cytometric detection of the cytopathogenicity and downmodu
viruses. In each case, cells were analyzed 6 days postinfection, at the time of pe
of cells of different sizes (forward scatter). The left and right peaks show theFIG. 3. CD41 lymphocyte counts in rhesus monkeys inoculated with
SHIV-89.6P (MM130 and 131) and its molecular clone cl 64 (MM189,
200, 210, and 215). Data are expressed as the mean values of the
1 cloned virus remained healthy, and no detectable sign of
disease of any kind was observed during the observation
a
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9LESS PATHOGENIC CLONES FROM SHIV-89.6Pperiod (33 weeks for MM210 and 215 and more than 1
year for MM189 and 200).
Histopathological analysis
Two of the four cl 64-infected monkeys (MM210 and
MM215) were euthanized 33 weeks after inoculation and
autopsied to collect the lymphoid tissues. The monkeys
infected with parental SHIV-89.6P (MM130 and MM131)
developed acute AIDS. The histopathology of these mon-
keys exhibited the severe thymic involution and cell loss
in both the paracortex of the lymph nodes and the peri-
arterial lymphatic sheath of the spleen. Representative
histopathological findings are shown in Figs. 5D to 5F. In
contrast, MM210 and MM215, which were infected with
the 89.6P clone 64, did not show severe thymic atrophy
or T-zone depletion in the lymph nodes or spleen (Figs.
5A to 5C). These histopathological features are similar to
those of nonpathogenic SHIV-NM-3rN-infected monkeys
(data not shown).
DISCUSSION
This report describes the construction and evaluation
of infectious molecular clones that were derived from
FIG. 4. Plasma viral RNA loads of the macaques infected with
SHIV-89.6P (MM130 and 131) and its molecular clone 64 (MM189, 200,
210, and 215). Plasma viral RNA loads were measured by RT-PCR as
described under Materials and Methods. Data are expressed as the
mean values of results from each monkey with standard deviation.
T
Anti-HIV-1 env Antibod
Virus Monkey 0 1 2
SHIV cl 64 MM210 — — — 1
MM215 — — — 1
MM189 — — — 1
MM200 — — 1:16 1
SHIV-89.6P MM130 — — —
MM131 — — — —SHIV-89.6P in order to understand the acute pathogen-
esis of this virus. Four SHIV-89.6P-derived molecular
clones were constructed and evaluated in vitro, and one
of them was evaluated in vivo. Their characteristics were
compared with SIVmac239, SHIV NM-3rN, and parental
SHIV-89.6P viruses.
In our experiment, HSC-F cells, infected with strongly
pathogenic SHIV-89.6P rapidly downmodulated the CD4
molecules on the surface of the cells during the viral
replication. On the other hand, infection with nonpatho-
genic SHIV NM-3rN (Kuwata et al., 1995) or SIVmac239,
which is a chronically pathogenic virus and does not
cause acute CD4 depletion at an early stage of infection
in vivo (Evans et al., 1999), caused very weak CD4 down-
modulation in these cells. Therefore, the ability of these
viruses to replicate in HSC-F cells and to downmodulate
CD4 in vitro seemed to coincide with their in vivo patho-
genicities. Interestingly, of the four constructed SHIV-
89.6P molecular clones, one (cl 18) showed very weak
CD4 downmodulation, while the other three (cl 64, cl 69,
and cl 71) downmodulated CD4 with the same efficiency
as the uncloned virus. This suggests that the uncloned
parental virus population includes genetic variants with
different cytopathogenic abilities.
The partial or complete recovery of CD4 cells in mon-
keys after infection with cl 64 and the development of a
strong antiviral antibody response were also observed
with SHIV-89.6P KB9-infected monkeys, which did not
develop an AIDS-like disease (Reimann et al., 1999).
The plasma viral RNA level of cl 64 was decreased
substantially soon after it reached the peak at 2 weeks
postinfection in each of the infected monkeys, although
the parental virus replication persisted at a high level
even after 13 weeks.
Correlations between the level of HIV-1 replication and
the disease progression have been reported in HIV-
infected humans as well as in SIV-infected macaque
monkeys (Mellors et al., 1996; Lifson et al., 1997; Haaft et
l., 1998). A similar correlation was observed with some
HIV constructs, in which acquisition of pathogenicity by
n vivo passages or genetic modifications was always
ssociated with increased rates of viral replication
s in Infected Monkeys
Weeks postinfection
4 6 8 10 13
1:128 1:128 1:256 1:1024 .1:2048
1:64 1:256 1:512 1:1024 1:1024
1:16 1:64 1:256 1:1024 1:2048
1:256 1:256 1:512 1:1024 1:2048
— — — — —ABLE 1
y Titer
3
:64
:32
:16
:256
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10 KOZYREV ET AL.(Reimann et al., 1996a; Joag et al., 1999). In the present
tudy, the constructed SHIV-89.6P molecular clone (cl 64)
ad a reduced pathogenicity, but the time of its peak of
lasma viral RNA level, 2 weeks postinfection, was sim-
lar to that of the parental SHIV-89.6P virus. This sug-
ests that the initial replication of the obtained clone in
ivo is independent of its pathogenic abilities.
The cl 64 clone failed to result in an acute AIDS-like
isease at an early stage of infection. Interestingly, a
imilar disease progression takes place at the early
tages of HIV-1 infection in humans and at the early
tages of pathogenic SIV infection in monkeys. That is,
here is a short-term drop in the CD41 cell count followed
by recovery to the preinfection state with a subsequent
clinical latency of infection. During the latency period, the
virus accumulates a large amount of genetic variation
that may increase its chances of causing the disease.
This speculation was confirmed by the finding of positive
selection in the amino acid variation in SIV env and nef
CTL epitopes at the time when the SIVmac239-infected
macaques died (Evans et al., 1999). However, the paren-
tal SHIV-89.6P can successfully cause the disease even
at an early stage of infection soon after inoculation,
probably because of its highly divergent polyclonal form.
This hypothesis is consistent with a recent study of
macaque intravaginal infection by parental SHIV-89.6P
(Lu et al., 1998), in which the progression of the disease
at the early stages was observed in only a few cases.
This might be due to the mucosal barrier, which has
been shown to restrict the passage of various SIVs
(Enose et al., 1998). It is likely that only a few genetic
variants of the whole virus population can pass through
this barrier and infect T cells, and this would not be
enough to cause acute disease progression. Therefore
we speculate that the in vivo pathogenicity of a mono-
clonal virus might be reduced because of the difficulty in
accumulating a large amount of genetic variation at an
early stage of infection.
However, another possibility is that the constructed
clones lack the pathogenic determinants that allow the
parental virus to cause acute disease at an early stage of
infection in most infected monkeys. This is because the
molecular clones contain only the 39 half (vpu, tat, rev,
env, nef, and 39 LTR) of SHIV-89.6P, as was the case with
the construction of KB9 (Reimann et al., 1999). This prob-
lem must be solved by construction of a full SHIV-89.6P
genome, which we intend to do in future studies.
In conclusion, we have succeeded in creating four
infectious molecular clones of the SHIV-89.6P virus. One
of the clones showed no pathogenic abilities in vitro.
Another clone downregulated CD4 in vitro and showed a
high replication ability in the first 2 weeks after infection
in vivo, but the monkeys failed to develop an AIDS-like
disease at the early stage of infection. This suggests that
the characteristics of the obtained clones, other than
their replication ability, qualitatively differ from those ofthe parental virus, confirming the polyclonal nature of
SHIV-89.6P stock virus. The availability of the con-
structed clones will facilitate an understanding of the
mechanisms of SHIV-89.6P acute pathogenesis in vivo,
which has yet to be addressed.
MATERIALS AND METHODS
Cells and viruses
The human T cell line M8166 (Clapham et al., 1987)
was used as indicator cells to measure infectivity of the
viruses and also for virus reproduction. Establishment of
the HSC-F cell line has been previously described (Akari
et al., 1996). This is a cynomolgous monkey CD41 T cell
line from fetal liver that was immortalized by infection
with herpesvirus saimiri subtype C. This cell line ex-
presses some markers of activated or immature T cell
phenotypes including CD4 and CD8. The cells were
cultured in RPMI 1640 medium supplemented with 10%
fetal calf serum (FCS).
Rhesus macaque PBMCs were isolated from sodium
citrate-anticoagulated fresh rhesus macaque blood by
centrifugation with lymphocyte separation solution (Na-
calai Tesque, Inc., Kyoto, Japan). The cells were subse-
quently stimulated for 24 h with 25 mg/ml concanavalin A
and were cultured in RPMI 1640 medium containing 10%
FCS and 200–400 unit/ml IL-2.
The parental virus, SHIV-89.6P, has been previously
described (Reimann et al., 1996a,b). Briefly, this chimeric
virus contains the tat, rev, vpu, and env genes of HIV-1
isolate 89.6 is tropic to macrophages and T cells) in an
IVmac239 (nef-open) background. Importantly, the
HIV-89.6P env gene has a chimeric 39 end, which over-
aps with the nef gene from SIVmac239. The SIVmac239
imian immunodeficiency virus is a pathogenic molecu-
ar clone derived from rhesus monkeys (Kestler et al.,
990). The construction of SHIV-NM-3rN infectious virus
as reported previously (Kuwata et al., 1995). Briefly this
himeric virus contains the vpr, tat, rev, vpu, and env
enes of HIV-1 (NL432 clone) in an SIVmac239 (nef-open)
ackground. Virus-containing supernatants were frozen
nd were stored in liquid nitrogen.
onstruction of SHIV-89.6P molecular clones
To generate infectious molecular clones of SHIV-89.6P,
06 M8166 cells were inoculated with cell-free virus stock
of parental SHIV-89.6P. Cells harvested at the peak of
virus replication were used for high-molecular-weight
chromosomal DNA extraction. The 39 half of SHIV-89.6P
(from vpr to 39 LTR) was amplified by PCR using the
primers NHEMAvpr-F (59-GAGCTAGCATAAATGGAA-
GAAAGACCTCCAGAAA-39) and MAU5Eco-R (59-AA-
GAATTCTGCTAGGGATTTTCCTGCTTCGGTT-39). The un-
derlines indicate an NheI site and an EcoRI site, respec-
tively. After amplification, the 39 half was ligated to the 59
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11LESS PATHOGENIC CLONES FROM SHIV-89.6Phalf of SIVmac239 using the SpeI and EcoRI sites. The
obtained plasmids were multiplied by cloning in Esche-
richia coli (XL1Blue) bacteria cells.
In vitro infection and production of virus stock
To generate virus stock with a high titer, samples of
plasmid DNA were transfected into 2 3 106–3 3 106
M8166 cells by the DEAE-dextran method (Kuwata et al.,
1995). Syncytium formation as a cytopathic effect (CPE)
induced by the SHIVs was checked by microscope, and
at the time of peak CPE appearance, the virus-containing
supernatant was harvested and stored in liquid nitrogen.
The titer of the stored virus was evaluated by TCID50
measurement.
To investigate the growth kinetics of newly obtained
clones in vitro, HSC-F cells and monkey PBMCs were
infected with 104 TCID50 per milliliter of filtered cell-free
irus stock, and the reverse transcriptase activity was
easured by RT assay (Kuwata et al., 1995) along with
iral replication.
noculation of rhesus monkeys with the SHIV clone
Monkeys were treated in accordance with regulations
pproved by the Institutional Animal Care and Use Com-
FIG. 5. Representative histopathological findings of lymphoid tissu
64-infected monkey (MM215). (A–C) MM215, which was infected with 8
MM130, which was infected with SHIV-89.6P. This monkey developed A
E) spleen, (C and F) lymph node (hematoxylin and eosin stained, origiittee of the Institute for Virus Research, Kyoto Univer-
ity. Four 2-year-old rhesus macaques (MM210, MM215,M189, and MM200) were inoculated with the newly
btained SHIV-89.6P clone (SHIV-89.6P cl 64). Two ani-
als (MM210 and MM215) were inoculated with 1 ml of
irus stock containing 90 TCID50, and the other two
(MM189 and MM200) were inoculated with 2 ml of virus
stock containing 105 TCID50. All animals were housed in
ur monkey storage facility, the health conditions of
hich were examined weekly. Blood anticoagulated with
odium citrate was collected weekly for the first 4 weeks,
t 2-week intervals for the next 6 weeks, and at 4-week
ntervals thereafter. For autopsy, animals were sedated
ith ketamine and then were finally narcotized with 10 ml
f Nembutal.
ollecting and processing of blood and tissue
amples
PBMCs and plasma samples were isolated by centrif-
gation of the collected blood with sodium citrate anti-
oagulant agent. Isolated plasma samples were frozen
t 280°C and subsequently used for viral RNA extraction
nd antibody titer quantitation. One million isolated
BMCs were used for evaluation of CD41 and CD81 T
lymphocyte concentration by FACS analysis. Another 106
PBMCs were used for virus isolation. MM210 and
a parental SHIV-89.6P-infected monkey (MM130) and a 89.6P clone
ne 64. This monkey was euthanized at 33 weeks after infection. (D–F)
was euthanized at 26 weeks after infection. (A and D) Thymus, (B and
gnification 3100).es in
9.6P cloMM215 were euthanized and subjected to autopsy for
histopathological observation.
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12 KOZYREV ET AL.Plasma viral RNA quantitation
The SHIV RNA quantitative assay was performed by
reverse transcriptase PCR (RT-PCR) for the SIV gag re-
gion using the primers SIVII-696F (59-GGAAATTACCCAG-
TACAACAAATAGG-39) and SIVII-784R (59-TCTATCAATTT-
TACCCAAGGCATTTA-39) and a Taqman RT-PCR kit (Per-
kin–Elmer, U.S.A.) (Suryanarayana et al., 1998). The virion
RNA in plasma samples was extracted with a Viral RNA
Kit (Qiagen, Germany). A labeled probe, SIVII-731T
(59-Fam-TGTCCACCTGCCATTAAGCCCG-Tamra-39), was
sed for detection of the PCR product. For each run, a
tandard curve was generated from a SHIV-89.6P-
nfected monkey standard plasma sample, which was
easured by the branched DNA method (Bayer Diagnos-
ics, U.S.A.).
D4/CD8 T lymphocyte immunophenotyping and
ematological evaluation
CD41 cell numbers in PBMCs isolated from the ma-
aques were calculated before and after inoculation with
he viruses. PBMCs were treated with anti-CD4 antibody
Nu-TH/1-PE; Nichirei, Japan) and examined on a
ACScan analyzer (Becton–Dickinson) according to the
anufacturer’s recommendations. Absolute lymphocyte
ounts in the blood were determined with an automated
lood cell counter (F-820; Sysmex, Japan).
nti-HIV antibody titers
Anti-HIV antibody titers were determined using a com-
ercial Serodia-HIV KIT (Fujirebio, Tokyo, Japan).
lasma samples were isolated from sodium citrate-anti-
oagulated blood and then were serially diluted and
outinely assayed. End-point titer was determined as the
ighest dilution to give a positive result.
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